Dexamethasone Acetate is a small molecule commercialized by Oculis, with a leading Phase III program in Ocular Inflammation;Ocular Pain (Eye Pain). According to Globaldata, it is involved in 9 clinical trials, of which 5 were completed, and 4 are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Dexamethasone Acetate’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData

The revenue for Dexamethasone Acetate is expected to reach an annual total of $548 mn by 2034 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Dexamethasone Acetate Overview

Dexamethasone acetate (DexNP, OC-118, OCS-01) is under development for the treatment of macular edema, diabetic macular edema and post cataract operation inflammation and pain. The tehrapeutic candidate is formulated as eye drop suspension and administered through ophthalmic route of administration. It is a nanoparticle composed of gamma-cyclodextrin dexamethasone complex. Dexamethasone is synthetic glucocorticoids which target glucocorticoid receptors. The drug candidate is a complex of drug and cyclodextrin nanoparticle developed based on solubilizing nano-particle (SNP) drug-delivery technology and OPTIREACH. It was also under development of posterior and intermediate uveitis, glaucoma and ocular inflammation after surgery.

Oculis Overview

Oculis is a biopharmaceutical company that develops and commercializes topical treatments for acute optic neuritis, chronic back, glaucoma and front-of-the-eye ophthalmic diseases. The company is headquartered in Zug, Switzerland.
The operating loss of the company was CHF80.7 million in FY2023, compared to an operating loss of CHF32.4 million in FY2022. The net loss of the company was CHF88.8 million in FY2023, compared to a net loss of CHF38.7 million in FY2022.

For a complete picture of Dexamethasone Acetate’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.